These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9329611)

  • 1. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up.
    Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O
    Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptors: status and effect on breast cancer patients.
    Mansour OA; Zekri AR; Harvey J; el-Ahmady O
    Anticancer Res; 1997; 17(4B):3107-10. PubMed ID: 9329612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Muñoz M; Farrus B; Latre ML; Gimenez N; Hage M; Estape J; Ballesta AM
    Anticancer Res; 1996; 16(4B):2295-300. PubMed ID: 8694559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
    Surgery; 2003 Feb; 133(2):219-21. PubMed ID: 12605184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.
    Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F
    Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer.
    Robertson KW; Reeves JR; Smith G; Keith WN; Ozanne BW; Cooke TG; Stanton PD
    Cancer Res; 1996 Aug; 56(16):3823-30. PubMed ID: 8706030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed müllerian tumors). Clinicopathologic study of 82 cases.
    Costa MJ; Walls J
    Cancer; 1996 Feb; 77(3):533-42. PubMed ID: 8630962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
    Iwase H; Itoh Y; Kuzushima T; Yamashita H; Iwata H; Toyama T; Hara Y; Kobayashi S
    Cancer Detect Prev; 1997; 21(1):29-35. PubMed ID: 9043760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
    Pirinen R; Lipponen P; Syrjänen K
    Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
    Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
    Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers.
    Thor AD; Edgerton SM; Liu S; Moore DH; Kwiatkowski DJ
    Clin Cancer Res; 2001 Aug; 7(8):2415-24. PubMed ID: 11489821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.